Shots:

• Nykode to receive $30M up front & $20M equity investment representing a premium of 20% on a 30-day volume-weighted average price & $875M milestone along with royalties on sales of commercialized products
• The agreement combines Regeneron’s antigen selection expertise & VelociSuite in vivo models with Nykode’s modular vaccine platform and expertise in vaccine design to develop vaccines. The agreement includes 5 programs i.e., 3 in cancer & 2 in infectious disease
• Regeneron will lead research cost along with clinical, regulatory, manufacturing & commercialization activities. Nykode will be responsible for vaccine generation, characterization & product supply through the end of P-I trials

Click here to­ read full press release | Ref: Regeneron | Image: LinkedIn